Patent EP0234670B1 successfully refreshed from Google Patents.
EP0234670B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Sustained-release pharmaceutical formulation containing xanthan gum
Assignee: Boots Co PLC
•
Filing: 1987-01-06
•
Granted: 1992-06-24
•
Expires: 2007-01-06
Abstract
Abstract Prepn. of compsn. comprising a compressed mixt. of a pharmacologically active ingredient (I) and 7.5-28 wt.% of the compsn. of a sustained release carrier (II) comprising a major proportion of xanthan gum comprises mixing (I) with (II) and compressing the mixt. to produce a solid formulation. Pref. (II) comprises at least 90 wt.% xanthan gum. Pref. the ratio of (II) to (I) is 1:10 to 1:1.
Inventors
- 👤 Mahendra Govind Pankhania
- 👤 Colin David Melia
- 👤 John Francis Lampard
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 07:17
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
119 words
A solid sustained release pharmaceutical formulation comprising a compressed mixture of a pharmacologically active ingredient and a sustained release carrier comprising xanthan gum characterised in that the sustained release carrier comprises a major proportion of xanthan gum and is present in the formulation to an extent of 7.5-28% by weight, and that the formulation is adapted to provide sustained release both in the stomach and in the intestines, except for a formulation wherein the sustained release carrier comprises a mixture of 15-50 parts by weight dimethylpolysiloxane, 30-100 parts by weight silicic acid, 30-100 parts by weight mannans or galactans or a mixture of mannans and galactans , 50-150 parts by weight xanthans and 5-75 parts by weight micronized seaweed.
Claim 2
Dependent Claim
17 words
A formulation according to claim 1 in which the pharmacologically active ingredient comprises a non-steroidal anti-inflammatory agent.
Claim 3
Dependent Claim
23 words
A formulation according to any one of the preceding claims wherein the xanthan gum comprises greater than 10% by weight of the formulation.
Claim 4
Dependent Claim
19 words
A formulation according to any one of the preceding claims wherein the xanthan gum is the sustained release carrier.
Claim 5
Dependent Claim
21 words
A formulation according to any one of the preceding claims comprising 15 to 28% by weight of the sustained release carrier.
Claim 6
Dependent Claim
26 words
A formulation according to any one of claims 1 to 3 or 5 wherein the sustained release carrier comprises at least 75% by weight xanthan gum.
Claim 7
Dependent Claim
26 words
A formulation according to any one of claims 1 to 3 or 5 wherein the sustained release carrier comprises at least 90% by weight xanthan gum.
Claim 8
Dependent Claim
25 words
A formulation according to any one of claims 1,2,4,6 or 7 comprising 10 to 25% by weight of the formulation of the sustained release carrier.
Claim 9
Dependent Claim
31 words
A formulation according to any one of the preceding claims wherein the ratio of sustained release carrier to pharmacologically active ingredient is in the range 20:1 to 1:20 parts by weight.
Claim 10
Dependent Claim
28 words
A formulation according to any one of the preceding claims wherein the ratio of sustained release carrier to pharmacologically active ingredient is in the range 1:10 to 1:1.
Claim 11
Dependent Claim
25 words
A formulation according to any one of the preceding claims wherein the pharmacologically active ingredient comprises an arylalkanoic acid or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
23 words
A formulation according to any one of the preceding claims wherein the pharmacologically active ingredient comprises ibuprofen or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
17 words
A formulation according to claim 12 comprising 75-90% by weight ibuprofen or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
39 words
A formulation according to either one of claims 12 and 13 comprising 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum and 75-90% by weight of ibuprofen or a pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim
28 words
A formulation according to any one of claims 12 to 14 comprising 10-25% by weight xanthan gum and 75-90% by weight ibuprofen or a pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
24 words
A formulation according to any one of claims 1 to 11 wherein the pharmacologically active ingredient comprises flurbiprofen or a pharmaceutically acceptable salt thereof.
Claim 17
Dependent Claim
33 words
A formulation according to claim 16 comprising 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum and 20-50% by weight flurbiprofen or a pharmaceutically acceptable salt thereof.
Claim 18
Dependent Claim
17 words
A formulation according to any one of the preceding claims presented in the form of a tablet.
Claim 19
Dependent Claim
39 words
A process for the preparation of a formulation according to claim 1 comprising mixing the sustained release carrier comprising a major proportion of xanthan gum with the pharmacologically active ingredient and compressing the mixture to produce a solid formulation.
References Cited (Backward Citations)
BE901111A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.